No abstract available
MeSH terms
-
Adenine / administration & dosage
-
Adenine / analogs & derivatives*
-
Adenine / therapeutic use
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / therapeutic use*
-
Clinical Trials as Topic
-
Drug Therapy, Combination
-
Follow-Up Studies
-
Guanine / administration & dosage
-
Guanine / analogs & derivatives*
-
Guanine / therapeutic use
-
Hepatitis B Surface Antigens / analysis
-
Hepatitis B e Antigens / analysis
-
Hepatitis B, Chronic / diagnosis
-
Hepatitis B, Chronic / drug therapy*
-
Hepatitis B, Chronic / immunology
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use*
-
Lamivudine / administration & dosage
-
Lamivudine / therapeutic use*
-
Nucleosides / administration & dosage
-
Nucleosides / therapeutic use*
-
Organophosphonates / administration & dosage
-
Organophosphonates / therapeutic use*
-
Polyethylene Glycols / administration & dosage
-
Polyethylene Glycols / therapeutic use*
-
Pyrimidinones / administration & dosage
-
Pyrimidinones / therapeutic use*
-
Recombinant Proteins
-
Reverse Transcriptase Inhibitors / administration & dosage
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Telbivudine
-
Thymidine / analogs & derivatives
-
Time Factors
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Hepatitis B Surface Antigens
-
Hepatitis B e Antigens
-
Interferon alpha-2
-
Interferon-alpha
-
Nucleosides
-
Organophosphonates
-
Pyrimidinones
-
Recombinant Proteins
-
Reverse Transcriptase Inhibitors
-
Telbivudine
-
Lamivudine
-
Polyethylene Glycols
-
entecavir
-
Guanine
-
adefovir
-
peginterferon alfa-2b
-
Adenine
-
peginterferon alfa-2a
-
Thymidine